tetano
Editor, Senior Moderator
Npj Viruses
. 2024 Aug 6;2(1):28.
doi: 10.1038/s44298-024-00038-0. Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1
Stephanie K Lathrop[SUP] 1 [/SUP], Jordan J Clark[SUP] 2 3 [/SUP], Karthik Siram[SUP] 1 [/SUP], Robert Andreata-Santos[SUP] 2 3 4 [/SUP], Jeremy Yong[SUP] 2 3 [/SUP], Rebekah D Tee[SUP] 1 [/SUP], Clara J Davison[SUP] 1 [/SUP], Gagandeep Singh[SUP] 2 3 [/SUP], David Burkhart[SUP] 1 [/SUP], Florian Krammer[SUP] 2 3 5 6 [/SUP], Jay T Evans[SUP] 7 [/SUP]
Affiliations
Many different platforms have been used to develop highly protective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans. However, protection has eroded over time due to the emergence of antigenically diverse viral variants, especially the Omicron subvariants. One successful platform for the generation of SARS-CoV-2 vaccines are recombinant spike protein vaccines, of which two are licensed in the United States and Europe. Typically, purified recombinant protein antigens are poorly immunogenic and adjuvants must be included in the formulation. Here, we adjuvanted recombinant ancestral SARS-CoV-2 Wuhan-Hu-1 spike proteins with an emulsion formulation combined with synthetic Toll-like receptor (TLR) 4 and 7/8 agonists. This combination led to the induction of a Th1-skewed immune response that included high titers of antibodies against Wuhan-Hu-1 spike. These serum antibodies included neutralizing and cross-reactive antibodies that recognized the spike from multiple SARS-CoV-2 variants, as well as the receptor binding domain (RBD) from SARS-CoV-1. Despite an absence of robust cross-neutralization, vaccination against Wuhan-Hu-1 spike in the context of TLR-containing emulsions provided complete cross-protection against disease from a lethal challenge with XBB.1 in a stringent K18-hACE2 mouse model. We believe that the combination of recombinant spike antigens with TLR agonist-based emulsion formulations could lead to the development of next-generation SARS-CoV-2 vaccines that provide significant protection from future emerging variants.
. 2024 Aug 6;2(1):28.
doi: 10.1038/s44298-024-00038-0. Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1
Stephanie K Lathrop[SUP] 1 [/SUP], Jordan J Clark[SUP] 2 3 [/SUP], Karthik Siram[SUP] 1 [/SUP], Robert Andreata-Santos[SUP] 2 3 4 [/SUP], Jeremy Yong[SUP] 2 3 [/SUP], Rebekah D Tee[SUP] 1 [/SUP], Clara J Davison[SUP] 1 [/SUP], Gagandeep Singh[SUP] 2 3 [/SUP], David Burkhart[SUP] 1 [/SUP], Florian Krammer[SUP] 2 3 5 6 [/SUP], Jay T Evans[SUP] 7 [/SUP]
Affiliations
- PMID: 40295700
- DOI: 10.1038/s44298-024-00038-0
Many different platforms have been used to develop highly protective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans. However, protection has eroded over time due to the emergence of antigenically diverse viral variants, especially the Omicron subvariants. One successful platform for the generation of SARS-CoV-2 vaccines are recombinant spike protein vaccines, of which two are licensed in the United States and Europe. Typically, purified recombinant protein antigens are poorly immunogenic and adjuvants must be included in the formulation. Here, we adjuvanted recombinant ancestral SARS-CoV-2 Wuhan-Hu-1 spike proteins with an emulsion formulation combined with synthetic Toll-like receptor (TLR) 4 and 7/8 agonists. This combination led to the induction of a Th1-skewed immune response that included high titers of antibodies against Wuhan-Hu-1 spike. These serum antibodies included neutralizing and cross-reactive antibodies that recognized the spike from multiple SARS-CoV-2 variants, as well as the receptor binding domain (RBD) from SARS-CoV-1. Despite an absence of robust cross-neutralization, vaccination against Wuhan-Hu-1 spike in the context of TLR-containing emulsions provided complete cross-protection against disease from a lethal challenge with XBB.1 in a stringent K18-hACE2 mouse model. We believe that the combination of recombinant spike antigens with TLR agonist-based emulsion formulations could lead to the development of next-generation SARS-CoV-2 vaccines that provide significant protection from future emerging variants.